Metformin's Impact on Life Expectancy in Type 2 Diabetes

Mortality Benefits

The American College of Physicians recommends metformin for type 2 diabetes patients, particularly overweight individuals, due to its 27% reduction in all-cause mortality sustained over 17 years of follow-up 1, 2
Metformin reduced all-cause mortality by 36% (relative risk reduction, CI 9% to 55%, P = 0.011) compared to conventional therapy, translating to approximately 7 fewer deaths per 1000 patient-years 1, 2
The UKPDS 34 trial demonstrated a 42% relative risk reduction in diabetes-related death (CI 9% to 63%, P = 0.017) at initial follow-up, with benefits persisting at 17 years 1, 2
Metformin reduced myocardial infarction by 33% (6.3 fewer events per 1000 patient-years, P = 0.005) at extended follow-up 1, 2

The American College of Physicians suggests starting metformin as first-line monotherapy for newly diagnosed type 2 diabetes patients, particularly those who are overweight or obese, unless contraindicated 5, 6
The target dose of metformin is 1500-2000 mg daily for maximum glycemic and mortality benefit 5

Early addition of metformin to sulfonylureas resulted in increased risk for diabetes-related death (P = 0.039) compared with continued sulfonylureas alone 1, 2, 4
Metformin monotherapy has minimal hypoglycemia risk, but intensive therapy regimens showed approximately 30% annual hypoglycemia rates versus 1% in standard treatment groups 1, 2, 4